GZP’s professional team provides innovative, practical and quality services and believes that our first responsibility is to our clients.  Our experience enables us to provide value-added strategic consulting with consideration for the legal and regulatory framework of the medical product and with sensitivity to health care professionals and patients – our ultimate clients.

Management Team


Evan B. Siegel, M.Phil., Ph.D., President and CEO

Dr. Siegel founded Ground Zero Pharmaceuticals, Inc. (GZP) in 1999 from his consulting firm, Ground Zero Strategics, Ltd. He currently serves as its President and CEO, and is also the Chairman of the Board. Prior to GZP Evan served as Consultant and CEO to OXO Chemie Inc., Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc. (now Interleukin Genetics), and Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., North Carolina. Dr. Siegel has also held regulatory affairs and executive positions at Astra and Syntex, and was a Toxicology Reviewer at the US Food and Drug Administration, as well as Supervising Toxicologist and Chief of Special Services at the State of California’s Food and Drug Branch, Department of Health Services. He is the author of a number of published articles in peer-reviewed journals, the editor of books on drug development and author of chapters on nonclinical development, vaccine biotechnology, and quality assurance. He has Master and Doctor of Philosophy degrees in Virology and Molecular Biology and is an Adjunct Professor in the School of Pharmacy and Centre for Integrated Preclinical Drug Development, University of Queensland, Australia. He is a member of the Lt. Governor’s Biotechnology Advisory Committee to the California Economic Development Commission.


Tisha A. Templeton, Sr. Vice-President of Finance and Operations

Ms. Templeton specializes in the development of accounting and finance systems as well as the structure and execution of operational procedures, administration of human resource and benefit programs, and infrastructure building for small high technology firms. With over fifteen years in finance and operations, her experience includes management of financial and patient progress data streams from clinical trials, receipt of invoices and payments, development of project management SOPs and policies, and tracking of medical product development information from disparate sources. She also is the primary contact for all contracting with Ground Zero Pharmaceuticals, Inc. Ms. Templeton’s financial background includes designing and implementing the accounting systems for both OXO Chemie AG (a multinational pharmaceutical corporation) and Interleukin Genetics, Inc., formerly Medical Science Systems, Inc. (a biotechnology firm), in addition to several start up companies. She has also developed financial auditing systems for clinical trial programs. In addition, Ms. Templeton has been involved with business plan creation and production for a venture capital firm.


Chaline Strickland, Pharm.D., Vice President of Clinical Affairs

Dr. Strickland is a clinical pharmacologist with over twenty years of experience in the pharmaceutical and biotechnology industries with a concentration in pharmacogenetics and clinical drug development. Focusing on the needs of small drug and biologics companies in her present senior position at GZP, Dr. Strickland provides integrated strategic regulatory guidance based on her knowledge of the multiple disciplines critical to the medical product development process: clinical, statistical, regulatory, and nonclinical. She leads and coordinates multi-disciplinary teams to perform strategic program assessments and preparation of data packages for submission to the FDA. Her specific experience includes project management, clinical development and laboratory discovery of pharmaceuticals and biologics at OXO Chemie Inc., Tularik, Inc., and the MD Anderson Cancer Center. She has been involved with more than 30 IND programs across ten therapeutic areas (including oncology, CNS disease, infectious disease and somatic cell vaccines) from Pre-Phase 1 through Phase 3, and several NDA and BLA submissions to the US FDA. Some of these programs have involved molecules with Orphan Drug status in both the US and Europe, and Fast Track Designation in the US. Her Bachelor of Science degree in Molecular Biology was granted by the University of Texas in Austin. She received her Pharm. D. Degree from the University of California, San Francisco and completed a research fellowship conducting pharmacogenetics clinical studies.

The Board Of Directors

Our Board of Directors is composed of a small multinational dedicated group of professionals with extensive industry experience, grounded in academic excellence.

Technical Team

Each technical team member from GZP’s family to perform services on individual client projects is selected with the utmost care by the management team. The required experience and specialization for a program are identified and matched to the appropriate individual team member in each applicable technical discipline. This identification and the overall coordination by a highly experienced, multi-disciplinary Project Manager provide a solid foundation for successful execution of the client program and meeting of targeted future milestones.


GZP maintains close partnerships with carefully identified firms who possess additional expertise as needed and appropriate for specific programs and projects. These include data management, clinical monitoring, preclinical/non-clinical testing, and clinical site management. These partners are carefully vetted and share the same philosophies and business ethics as GZP.